ClinicalThought
View More
Deciding which patients with chronic hepatitis B should be treated is not as simple as determining if their ALT and DNA levels fall above guideline thresholds. Here’s my take.
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Preventing mother-to-child transmission of HBV infection is critical to ensure the long-term health of the newborn. Here’s how we can prevent infection in infants born to mothers with HBV infection.
Maria Buti, MD
Released: April 29, 2020
The early detection of HCC in patients with chronic HBV infection means the difference between curable vs terminal disease. Here is how I ensure I do not miss HCC in my patients.
Steven L. Flamm, MD
Released: June 16, 2020
What are the pros and cons of discontinuing oral therapy with nucleos(t)ide analogues in patients with chronic HBV infection? Here’s my take.
Pietro Lampertico, MD, PhD
Released: July 10, 2020
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.